Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

The largest ever clinical trial of T cell therapy for solid tumours has ended, heralding a new era for precision T cell ...

Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

From cutting-edge treatment methods to the integration of new technologies, the International Conference on Advances in Radiation Oncology (ICARO-4) promises to inspire and equip conference attendees ...

The global sales of central venous catheters (CVC) are estimated to be valued at USD 2,861.0 million in 2024 and are expected ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the fourth quarter of 2026 SAN DIEGO, Nov. 07, ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Co-authored by investigators of VHIO's Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results of a ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, ...